MannKind (NASDAQ:MNKD) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.01, reports. MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%.
MannKind (NASDAQ MNKD) traded down $0.11 during mid-day trading on Tuesday, reaching $3.16. 3,111,461 shares of the company’s stock were exchanged, compared to its average volume of 5,490,000. The firm has a market cap of $363.00, a P/E ratio of -11.70 and a beta of 3.18. The company has a debt-to-equity ratio of -0.43, a quick ratio of 0.28 and a current ratio of 0.31. MannKind has a 12 month low of $0.67 and a 12 month high of $6.96.
In other MannKind news, VP Stuart A. Tross acquired 39,840 shares of the business’s stock in a transaction on Thursday, December 21st. The stock was bought at an average price of $2.52 per share, for a total transaction of $100,396.80. Following the acquisition, the vice president now owns 59,840 shares in the company, valued at $150,796.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.10% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3226713/mannkind-mnkd-announces-earnings-results.html.
MannKind Company Profile
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.